Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan
Dermatitis® · 2026
DOI: 10.1089/derm.2025.0004 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Dermatitis®, 2026. Verfasst von Teppei Hagino und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Background
Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited.
Objective
To evaluate the real-world effectiveness and safety of lebrikizumab on Japanese patients with AD.
Methods
This two-center study included 126 Japanese patients with moderate-to-severe AD treated with lebrikizumab plus topical corticosteroids for 16 weeks. Eczema area and severity index (EASI), investigator’s global assessment (IGA), peak-pruritus (PP)-numerical rating scale (NRS), sleep quality NRS, AD control tool (ADCT), dermatology life quality index (DLQI), patient-oriented eczema measure (POEM), immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) were assessed during the treatment.
Results
Lebrikizumab reduced all clinical indexes at week 4, which was maintained until week 16. The achievement rates of EASI 50, 75, 90, 100, and IGA 0/1 at week 16 were 83.1%, 57.1%, 27.3%, 11.7%, and 33.3%, respectively. The achievement rates of ≥4-point reduction in PP-NRS, sleep quality NRS, or DLQI, ADCT
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino
Zitieren
APA
Hagino, T., Uchiyama, A., Onda, M., Kosaka, K., Araki, T., Motegi, S. I., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis®. https://doi.org/10.1089/derm.2025.0004
Vancouver
Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis®. 2026. doi:10.1089/derm.2025.0004
BibTeX
@article{Hagino2026,
author = {Hagino, Teppei and Uchiyama, Akihiko and Onda, Marina and Kosaka, Keiji and Araki, Takeshi and Motegi, Sei-Ichiro and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan},
journal = {Dermatitis®},
year = {2026},
doi = {10.1089/derm.2025.0004}
}
EUVIMED